Abstract
Genital herpes is one of the most common sexually transmitted diseases globally, and is associated with significant physical and psychological morbidity. However, upwards of 90% of infected individuals are unaware they are infected. Genital herpes is caused by herpes simplex virus type 1 (HSV-1) or herpes simplex type 2 (HSV-2). While there are differences between HSV-1 and HSV-2, both strains can cause ocular, oral, cutaneous and genital infections. HSV must come in contact with mucosal surfaces or abraded skin to initiate infection. Once infected, HSV persists indefinitely in a dormant state within sensory nerve ganglia until it is reactivated and causes a recurrent infection (Herpes simplex virus infections. 2. 2nd ed. Detroit: Charles Scribners & Sons; 2010. p. 823–828; Groves Am Fam Physician 93(11):928, 2016; Solomon et al. N Engl J Med 375(7):666, 2016; Bernstein et al. Clin Infect Dis 56(3):344–51, 2013) The herpes virus typically causes painful ulcerations at the site of infection, but these lesions do not have to be present to transmit the infection (asymptomatic shedding). On the basis of clinical examination, it is often impossible to determine definitively whether a first symptomatic episode of genital herpes is initial or recurrent disease. There are several different modalities to test for HSV infection, but PCR has emerged as the most reliable and sensitive method to confirm infection. A primary episode of HSV should be treated with oral antiviral therapy to prevent prolonged clinical illness with severe genital ulcerations. Prevention of genital HSV should primarily focus on decreasing overall HSV transmission and decreasing the morbidity and psychological stress for those already infected.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Herpes simplex virus infections, vol. 2, 2010. 2nd ed. Detroit: Charles Scribners & Sons. p. 823–8.
Groves MJ. Genital herpes: a review. Am Fam Physician. 2016;93(11):928. http://www.ncbi.nlm.nih.gov/pubmed/27281837
Solomon CG, Gnann JW Jr, Whitley RJ. Genital herpes. N Engl J Med. 2016;375(7):666. http://search.proquest.com/docview/1813629926
Bernstein DI, Bellamy AR, Hook EW 3rd, et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis. 2013;56(3):344–51. http://www.ncbi.nlm.nih.gov/pubmed/23087395. https://doi.org/10.1093/cid/cis891.
Fatahzadeh M. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J Am Acad Dermatol. 2007;57(5):737–63. http://www.sciencedirect.com/science/article/pii/S0190962207010456. https://doi.org/10.1016/j.jaad.2007.06.027.
Gutierrez KM. Rethinking herpes simplex virus infections in children and adolescents. J Pediatr. 2007;151(4):336–8. http://www.sciencedirect.com/science/article/pii/S0022347607005562. https://doi.org/10.1016/j.jpeds.2007.05.052.
Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2007;370(9605):2127–37. http://www.sciencedirect.com/science/article/pii/S0140673607619084. https://doi.org/10.1016/S0140-6736(07)61908-4.
Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2—United States, 1999–2010. J Infect Dis. 2014;209(3):325–33. http://www.ncbi.nlm.nih.gov/pubmed/24136792. https://doi.org/10.1093/infdis/jit458.
Xu F. Seroprevalence of herpes simplex virus type 1 in children in the United States. J Pediatr. 2007;151(4):374–7. http://www.sciencedirect.com/science/article/pii/S0022347607004428. https://doi.org/10.1016/j.jpeds.2007.04.065.
Rana RK, Pimenta JM, Rosenberg DM, et al. Sexual behaviour and condom use among individuals with a history of symptomatic genital herpes. Sex Transm Infect. 2006;82(1):69–74. http://www.ncbi.nlm.nih.gov/pubmed/16461610. https://doi.org/10.1136/sti.2004.012989.
U.S. Preventive Services Task Force. Behavioral counseling to prevent sexually transmitted infections: U.S. preventive services task force recommendation statement. Ann Intern Med. 2008;149(7):W95. http://www.annals.org/content/149/7/491.abstract
Auslander BA, Catallozzi M, Davis G, Succop PA, Stanberry LR, Rosenthal SL. Adolescents’ and young women’s use of a microbicide surrogate product when receiving oral sex. J Pediatr Adolesc Gynecol. 2014;27(1):37–40. http://www.ncbi.nlm.nih.gov/pubmed/24315715. https://doi.org/10.1016/j.jpag.2013.08.013.
Fanfair R, Zaidi A, Taylor L, Xu F, Gottlieb S, Markowitz L. Trends in seroprevalence of herpes simplex virus type 2 among non-hispanic blacks and non-hispanic whites aged 14 to 49 years—United States, 1988 to 2010. Sex Transm Dis. 2013;40(11):860–4. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00007435-201311000-00008. https://doi.org/10.1097/OLQ.0000000000000043.
Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296(8):964–73. https://doi.org/10.1001/jama.296.8.964.
Gnann JW, Whitley RJ. Genital herpes. N Engl J Med. 2016;375(7):666–74.
Kimberlin DW, Rouse DJ. Genital herpes. N Engl J Med. 2004;350(19):1970–7.
Ward PL, Roizman B. Herpes simplex genes: the blueprint of a successful human pathogen. Trends Genet. 1994;10:267–74.
Garland SM, Steben M. Genital herpes. Best Pract Res Clin Obstet Gynaecol. 2014;28(7):1098–110. http://www.ncbi.nlm.nih.gov/pubmed/25153069. https://doi.org/10.1016/j.bpobgyn.2014.07.015.
Kukhanova M, Korovina A, Kochetkov S. Human herpes simplex virus: life cycle and development of inhibitors. Biochem Moscow. 2014;79(13):1635–52. http://www.ncbi.nlm.nih.gov/pubmed/25749169. https://doi.org/10.1134/S0006297914130124.
Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med. 2000;342(12):844–50. http://content.nejm.org/cgi/content/abstract/342/12/844. https://doi.org/10.1056/NEJM200003233421203.
Fife KH, Williams JA, Thomas AL, Ofner S, Katz BP, Fortenberry JD. Herpes simplex virus type 2 infection in young adult women: risk factors for infection and frequency of viral shedding. Sex Transm Dis. 2010;37(4):248. http://www.ncbi.nlm.nih.gov/pubmed/20216477. https://doi.org/10.1097/OLQ.0b013e3181d4f866.
Merin A, Pachankis JE. The psychological impact of genital herpes stigma. J Health Psychol. 2011;16(1):80–90. http://journals.sagepub.com/doi/full/10.1177/1359105310367528. https://doi.org/10.1177/1359105310367528.
Sauerbrei A. Optimal management of genital herpes: current perspectives. Infect Drug Resist. 2016;9:129–41. http://www.ncbi.nlm.nih.gov/pubmed/27358569. https://doi.org/10.2147/IDR.S96164.
Dhankani V, Kutz JN, Schiffer JT. Herpes simplex virus-2 genital tract shedding is not predictable over months or years in infected persons. PLoS Comput Biol. 2014;10(11):e1003922. http://www.ncbi.nlm.nih.gov/pubmed/25375183. https://doi.org/10.1371/journal.pcbi.1003922.
Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis. 2004;190(8):1374–81. http://www.jstor.org/stable/30078058. https://doi.org/10.1086/424519.
Tronstein E, Johnston C, Huang M, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA. 2011;305(14):1441–9. https://doi.org/10.1001/jama.2011.420. https://doi.org/10.1001/jama.2011.420.
Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest. 1997;99(5):1092–7. http://www.ncbi.nlm.nih.gov/pubmed/9062368. https://doi.org/10.1172/JCI119237.
Sexually transmitted diseases: summary of 2015 CDC treatment guidelines. J Miss State Med Assoc. 2015;56(12):372. http://www.ncbi.nlm.nih.gov/pubmed/26975162
Singh A, Preiksaitis J, Romanowski B. The laboratory diagnosis of herpes simplex virus infections. Can J Infect Dis Med Microbiol. 2005;16(2):92–8. https://doi.org/10.1155/2005/318294.
Ramaswamy M, Mcdonald C, Smith M, et al. Diagnosis of genital herpes by real time PCR in routine clinical practice. Sex Transm Infect. 2004;80(5):406–10. http://www.ncbi.nlm.nih.gov/pubmed/15459412. https://doi.org/10.1136/sti.2003.008201.
Moseley RC, Corey L, Benjamin D, Winter C, Remington ML. Comparison of viral isolation, direct immunofluorescence, and indirect immunoperoxidase techniques for detection of genital herpes simplex virus infection. J Clin Microbiol. 1981;13(5):913–8. http://jcm.asm.org/content/13/5/913.abstract
Ratnam S, Severini A, Zahariadis G, Petric M, Romanowski B. The diagnosis of genital herpes – beyond culture: an evidence-based guide for the utilization of polymerase chain reaction and herpes simplex virus type-specific serology. Can J Infect Dis Med Microbiol. 2007;18(4):233–40. https://doi.org/10.1155/2007/505364.
Strick LB, Wald A. Diagnostics for herpes simplex virus: is PCR the new gold standard? Mol Diag Ther. 2006;10(1):17–28. http://www.ingentaconnect.com/content/adis/mdt/2006/00000010/00000001/art00002. https://doi.org/10.1007/BF03256439.
Shevlin E, Morrow RA. Comparative performance of the uni-gold(TM) HSV-2 rapid: a point-of-care HSV-2 diagnostic test in unselected sera from a reference laboratory. J Clin Virol. 2014;61(3):378–81. http://www.ncbi.nlm.nih.gov/pubmed/25200648. https://doi.org/10.1016/j.jcv.2014.08.012.
Warren T, Gilbert L, Mark H. Availability of serologic and virologic testing for herpes simplex virus in the largest sexually transmitted disease clinics in the United States. Sex Transm Dis. 2011;38(4):267. http://www.ncbi.nlm.nih.gov/pubmed/21139516. https://doi.org/10.1097/OLQ.0b013e318202780a.
Krantz I, Löwhagen G-B, Ahlberg BM, Nilstun T. Ethics of screening for asymptomatic herpes virus type 2 infection. BMJ Br Med J. 2004;329(7466):618–21. http://www.jstor.org/stable/25469080. https://doi.org/10.1136/bmj.329.7466.618.
Whittington WL, Celum CL, Cent A, Ashley RL. Use of a glycoprotein G-based type-specific assay to detect antibodies to herpes simplex virus type 2 among persons attending sexually transmitted disease clinics. Sex Transm Dis. 2001;28(2):99–104. http://www.ncbi.nlm.nih.gov/pubmed/11234793. https://doi.org/10.1097/00007435-200102000-00007.
Wald A. Knowledge is power: a case for wider herpes simplex virus serologic testing. JAMA Pediatr. 2013;167(8):689–90. https://doi.org/10.1001/jamapediatrics.2013.459.
Roth AM, Van Der Pol B, Fortenberry JD, et al. Herpes simplex virus type 2 serological testing at a community court: predictors of test acceptance and seropositivity among female defendants. Int J STD AIDS. 2013;24(3):169–74. http://journals.sagepub.com/doi/full/10.1177/0956462412472442. https://doi.org/10.1177/0956462412472442.
Patwardhan V, Bhalla P. Role of type-specific herpes simplex virus-1 and 2 serology as a diagnostic modality in patients with clinically suspected genital herpes: a comparative study in indian population from a tertiary care hospital. Indian J Pathol Microbiol. 2016;59(3):318–21. http://www.ncbi.nlm.nih.gov/pubmed/27510668. https://doi.org/10.4103/0377-4929.188104.
Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med. 2008;168(11):1137–44. https://doi.org/10.1001/archinte.168.11.1137
Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350(1):11–20. http://content.nejm.org/cgi/content/abstract/350/1/11. https://doi.org/10.1056/NEJMoa035144.
DeJesus E, Wald A, Warren T, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis. 2003;188(7):1009–16. http://www.ncbi.nlm.nih.gov/pubmed/14513421. https://doi.org/10.1086/378416.
Warren T, Harris J, Brennan CA. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV. Clin Infect Dis. 2004;39(S5):S266. http://www.jstor.org/stable/4462962. https://doi.org/10.1086/422362.
Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS. Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir study group. J Infect Dis. 1994;169(6):1338. http://www.ncbi.nlm.nih.gov/pubmed/8195614
Wald A, Langenberg AGM, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA. 2001;285(24):3100–6. https://doi.org/10.1001/jama.285.24.3100
Caulfield P, Willis D. P57 to disclose or not to disclose. An exploration of the multi-disciplinary team’s role in advising patients about disclosure when diagnosed with genital herpes simplex virus (HSV). Sex Transm Infect. 2015;91(Suppl 1):A34. https://doi.org/10.1136/sextrans-2015-052126.100.
Davis A, Roth A, Brand JE, Zimet GD, Van Der Pol B. Coping strategies and behavioural changes following a genital herpes diagnosis among an urban sample of underserved midwestern women. Int J STD AIDS. 2016;27(3):207–12. http://journals.sagepub.com/doi/full/10.1177/0956462415578955. https://doi.org/10.1177/0956462415578955.
Royer HR, Falk EC, Heidrich SM. Genital herpes beliefs: implications for sexual health. J Pediatr Adolesc Gynecol. 2013;26(2):109–16. http://www.ncbi.nlm.nih.gov/pubmed/23337309. https://doi.org/10.1016/j.jpag.2012.11.007.
Wald A, Krantz E, Selke S, Lairson E, Morrow RA, Zeh J. Knowledge of partners’ genital herpes protects against herpes simplex virus type 2 acquisition. J Infect Dis. 2006;194(1):42–52. http://www.jstor.org/stable/30085806. https://doi.org/10.1086/504717.
Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis. 2002;185(1):45–52. http://www.jstor.org/stable/30138124. https://doi.org/10.1086/338231.
Mujugira A, Magaret AS, Celum C, et al. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial. J Infect Dis. 2013;208(9):1366–74. http://www.ncbi.nlm.nih.gov/pubmed/23901094. https://doi.org/10.1093/infdis/jit333.
Robinson NJ, Celum CL, Cohen MS. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection. J Infect Dis. 2005;191(3):S107.
Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS. 2008;22(5):601.
Mikuła T, Mian MM, Stańczak W, Cianciara J. The immune reconstitution inflammatory syndrome (IRIS) in HIV infected patient – case report. HIV AIDS Rev. 2007;6(3):25–31. http://www.sciencedirect.com/science/article/pii/S1730127010600768. https://doi.org/10.1016/S1730-1270(10)60076-8.
Acyclovir Pregnancy Registry and Valacyclovir Pregnancy Registry Interim Report, December 1997. Glaxo Wellcome, RTP, NC 27709.
Centers for Disease Control and Prevention: Metropolitan Atlanta Congenital Defects Program, revised January 1998. https://www.cdc.gov/ncbddd/birthdefects/macdp.html.
Cone RW, Hobson AC, Brown Z, et al. Frequent detection of genital herpes simplex virus DNA by polymerase chain reaction among pregnant women. JAMA. 1994;272(10):792–6. https://doi.org/10.1001/jama.1994.03520100054033. https://doi.org/10.1001/jama.1994.03520100054033.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Duroseau, N.H., Miller, R.R. (2020). Herpes Simplex Virus. In: Hussen, S. (eds) Sexually Transmitted Infections in Adolescence and Young Adulthood. Springer, Cham. https://doi.org/10.1007/978-3-030-20491-4_16
Download citation
DOI: https://doi.org/10.1007/978-3-030-20491-4_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-20490-7
Online ISBN: 978-3-030-20491-4
eBook Packages: MedicineMedicine (R0)